Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Follow-Up Questions
What is Scinai Immunotherapeutics Ltd (SCNI)'s P/E Ratio?
The P/E ratio of Scinai Immunotherapeutics Ltd is 0.2837
Who is the CEO of Scinai Immunotherapeutics Ltd?
Mr. Amir Reichman is the Chief Executive Officer of Scinai Immunotherapeutics Ltd, joining the firm since 2021.
What is the price performance of SCNI stock?
The current price of SCNI is $1.56, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Scinai Immunotherapeutics Ltd?
Scinai Immunotherapeutics Ltd belongs to Biotechnology industry and the sector is Health Care
What is Scinai Immunotherapeutics Ltd market cap?
Scinai Immunotherapeutics Ltd's current market cap is $1.4M
Is Scinai Immunotherapeutics Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Scinai Immunotherapeutics Ltd, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
